ABIONYX Pharma secures €33m funding for sepsis trial

1 min read | Published on 01 Jul 2026, 12:56 AM |Updated on 01 Jul 2026, 12:56 AM

Reviewed by

Suketu GScanX News Team

Key Highlights

ABIONYX Pharma has secured €33 million in funding, extending its financial visibility to the end of 2028. The company will launch a pivotal Phase 2b trial for CER-001 in sepsis by late 2026 and seek EMA approval for LCAT deficiency in early 2028. All shareholder resolutions were approved at the recent Combined General Meeting.

*this image is generated using AI for illustrative purposes only.

ABIONYX Pharma has secured funding totaling up to €33 million, providing financial visibility through the end of 2028 to support its strategic objectives. The company is entering a new phase of development focused on clinical execution and the monetization of its proprietary apoA-I-based technology platform. This financial strength allows ABIONYX Pharma to fully prioritize the development of CER-001 for sepsis and LCAT deficiency.

At the Combined General Meeting held at the company’s headquarters, all resolutions presented by the Board of Directors were adopted. The minutes and voting results will be available on the Company’s website. The company’s value creation strategy will now rely primarily on the quality of clinical data generated and the progressive monetization of its scientific platform.

Strategic Milestones and Funding Allocation

The secured capital will drive several key initiatives aimed at establishing CER-001 as a new standard of care. The company has outlined a clear timeline for its priority programs, which include clinical trials, regulatory submissions, and the development of new partnerships.

Program	Objective	Timeline
CER-001 for sepsis	Initiate pivotal Phase 2b clinical trial	By end of 2026
CER-001 for sepsis	First results expected	First half of 2028
CER-001 for LCAT deficiency	Validation of two GMP batches	2027
CER-001 for LCAT deficiency	Marketing authorization application to EMA	Early 2028

Focus on Execution and Platform Optimization

The Board of Directors and management are prioritizing rigorous execution of the announced programs. Key focus areas include adherence to clinical and GMP production timelines, generating data to support regulatory approvals, and maintaining rigorous financial management. ABIONYX Pharma will also actively pursue collaborations with academic, industrial, and technology partners to accelerate the commercialization of its recombinant apoA-I-based technology platform.

The company’s next financial press release, detailing the cash position and an update on Q2 2026 activity, is scheduled for August 27, 2026.

What specific criteria will ABIONYX use to identify potential partners for the monetization of its apoA-I-based technology platform?

How will the company manage its financial runway if the Phase 2b sepsis trial results are delayed beyond the first half of 2028?

What regulatory precedents in the sepsis space might influence the EMA's review of the CER-001 marketing authorization application?

Abionyx Pharma secures EUR 33 M financing for clinical trials

2 min read | Published on 18 Jun 2026, 11:06 AM |Updated on 18 Jun 2026, 11:06 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

ABIONYX Pharma raised EUR 18.7 million via a rights issue and EUR 10 million through bonds, securing EUR 33 million total. Funds will finance the Phase 2b sepsis trial and LCAT Deficiency MAA, extending cash runway into Q4 2028.

*this image is generated using AI for illustrative purposes only.

ABIONYX Pharma has successfully secured EUR 33 million in financing through a fully subscribed capital increase and an initial bond drawdown. The company raised EUR 18.7 million via a rights issue and EUR 10 million from the first tranche of a bond financing facility provided by Fenja Capital. These funds are earmarked to fully finance the Phase 2b clinical trial in sepsis and the Marketing Authorization Application (MAA) for LCAT Deficiency, extending the company's cash runway into Q4 2028.

The rights issue, launched on May 27, 2026, resulted in the issuance of 7,056,416 new shares at a subscription price of EUR 2.65 per share. Existing shareholders subscribed for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of guarantee commitments. Settlement and delivery of the new shares are expected on June 22, 2026, with admission to trading on Euronext Paris scheduled for the same date.

Rights Issue Allocation

Underwriting commitments were partially called to cover unsubscribed shares, totaling 4,888,546 new shares for EUR 12,954,646.90. The final gross amount of the rights issue reached EUR 18.7 million. Following the issuance, the company's share capital will consist of 42,568,071 shares.

Shareholder	Shares Before	% Voting Rights Before	Shares After	% Capital After	% Voting Rights After
DOMUNDI SAS	4,392,430	12.37%	4,430,165	10.41%	13.98%
ORSAY 53	2,331,000	6.56%	2,481,943	5.83%	4.77%
Luc Demarre	2,003,586	5.64%	2,022,453	4.75%	7.43%
Cyrille Tupin	1,592,214	4.48%	1,592,214	3.74%	5.41%
Fenja Capital II A/S	0	0.00%	1,002,579	2.36%	1.93%
Free Float	22,671,794	63.84%	28,518,086	66.99%	61.87%

Bonds Financing and Warrants

Fenja Capital provided the first tranche of EUR 10 million in non-convertible bonds, with issuance expected on June 25, 2026. A second tranche of EUR 4 million may be drawn in Q4 2026, subject to market capitalization and liquidity conditions. The bonds carry an interest rate of three-month EURIBOR plus 3.00% per annum, with a floor of 2.00%, and mature on May 26, 2028, extendable to November 26, 2028.

As part of the transaction, 2,240,424 warrants were issued to Fenja Capital, exercisable over five years at an initial price of EUR 3.71 per share. The warrants represent a potential dilution of 5.00% based on shares outstanding immediately after the transaction.

Use of Proceeds

The net proceeds from the transaction, estimated at approximately EUR 25.2 million, will be allocated to specific development milestones. EUR 10 million is designated for the Phase 2b sepsis trial, with study initiation planned for 2026 and topline data expected by the end of the first half of 2028. EUR 9 million will advance the LCAT Deficiency program toward an MAA submission to the EMA in early 2028. The remaining funds will support general corporate purposes and extend the cash runway into Q4 2028.

What are the potential market impacts if the Phase 2b sepsis trial topline data, expected in H1 2028, meets or exceeds efficacy endpoints?

How might the issuance of warrants to Fenja Capital influence ABIONYX's share price and investor sentiment over the next five years?

What strategic options will ABIONYX explore if the second tranche of EUR 4 million in bond financing is not drawn in Q4 2026 due to market conditions?